MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee
February 1, 2019
1:00 P.M.
Conference Center Room “A”
Indiana State Government Center South

1. Call to Order-Chair

2. Preferred Drug List: Therapeutic Class Re-Review - Discussion and Recommendations

3. Preferred Drug List: Therapeutic Class Re-Review
   a) Respiratory
      i. Antihistamine-Decongestant Combinations/2nd Generation Antihistamines
      ii. Antiviral Monoclonal Antibodies
      iii. Beta Adrenergics and Corticosteroids
      iv. Beta Agonists
      v. Bronchodilator Agents - Beta Adrenergic and Anticholinergic Combinations
      vi. Leukotriene Receptor Antagonists
      vii. Monoclonal Antibodies for the Treatment of Respiratory Conditions
      viii. Nasal Antihistamines/Nasal Anti-Inflammatory Steroids
      ix. Oral Inhaled Glucocorticoids
x. Phosphodiesterase-4 Inhibitors
xi. Pulmonary Antihypertensives

b) Anti-Infectives

i. Antivirals – Anti-Herpetic Agents
ii. Antivirals – Influenza Agents
iii. Cephalosporins – 3rd Generation
iv. Fluoroquinolones
v. Hepatitis C Agents
vi. Macrolides
vii. Ophthalmic Antibiotics
viii. Ophthalmic Antibiotics/Corticosteroid Combinations
ix. Oral Non-Systemic Antifungals
x. Otic Antibiotics
xi. Systemic Antifungals
xii. Topical Antifungals
xiii. Topical Antivirals
xiv. Topical Antivirals and Anti-Inflammatory Steroid Combinations
xv. Vaginal Antimicrobials

c) Cardiovascular

i. Angiotensin-Converting Enzyme (ACE) Inhibitors
ii. ACE Inhibitor Combinations
iii. Alpha Adrenergic Blockers
iv. Angiotensin II Receptor Antagonists (ARBs)
v. ARB Combinations
vi. Beta Adrenergic Blockers
vii. Beta Adrenergic Blockers with Diuretics
viii. Calcium Channel Blockers (CCBs)
ix. CCBs with HMG-CoA Reductase Inhibitors
x. Miscellaneous Cardiac Agents
d) Lipotropics
   i. Bile Acid Sequestrants
   ii. Fibric Acid Derivatives
   iii. HMG-CoA Reductase Inhibitors
   iv. Lipotropics

e) Antimigraine Agents
f) Electrolyte Depleters
g) Multiple Sclerosis Agents

4. Public Comment

5. Other Business

6. Adjourn